Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis

Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis

Submitted by admin on August 10, 2023 - 11:32am
Source: 
BioSpace
News Tags: 
Galera Therapeutics
avasopasem manganese
layoffs
oral mucositis
head and neck cancer
FDA
Headline: 
Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis
snippet: 

The FDA rejected on Wednesday Galera Therapeutics’ avasopasem manganese, which the company was proposing as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer.

Do Not Allow Advertisers to Use My Personal information